Anika Therapeutics Q3 2024 Earnings Update

On October 31, 2024, Anika Therapeutics, Inc. (NASDAQ: ANIK) announced its third-quarter financial results and outlined strategic updates during its earnings conference call. The company revealed the sale of its Arthrosurface division for approximately $10 million and plans to divest Parcus Medical. These actions aim to focus on Anika's hyaluronic acid (HA)-based products for osteoarthritis (OA) pain management and regenerative solutions. The restructuring will reduce the workforce from 325 to 225 employees and classify revenue streams for enhanced transparency.

Key Takeaways

• Anika sold Arthrosurface for about $10 million and intends to sell Parcus Medical.
• The workforce will decrease by approximately 30%.
• Integrity product displayed strong performance with 40% sequential growth in Q3.
• Progress noted in Hyalofast and Cingal products.
• Updated guidance anticipates 16% growth in 2024 for HA-focused products.
• Q3 revenues were $38.8 million, with a net loss of $29.9 million largely due to a $27 million impairment from the Arthrosurface sale.
• Anika expects 14% to 19% revenue growth in its commercial channel for 2024.
• Adjusted EBITDA is projected between $16 million and $18 million for 2024.
• The aim is to maintain cash flow neutrality during the transition.

Company Outlook

• A U.S. launch for Hyalofast is anticipated by 2026.
• Continued projections for 14% to 19% revenue growth in 2024.
• Long-term profitability expected from Regenerative Solutions.

Bearish Highlights

• Q3 revenues declined from the previous year.
• Significant net loss from Arthrosurface sale impairment.
• Revenue decline of 8% to 10% forecasted for the OEM channel in 2024.

Bullish Highlights

• Over 500 surgeries using Integrity conducted since its late 2023 launch.
• 7% increase in international OA pain sales.
• Core OA pain management business maintains strong EBITDA margins over 20%.

Misses

• Revenue fell due to lower sales from JNJ MedTech.
• Quarterly net loss influenced by Arthrosurface impairment.

Q&A Highlights

• Company aims to remain cash flow neutral for the full year.
• Estimated annual revenue from divested Arthrosurface business just over $25 million.
• Initial acquisition costs for Arthrosurface were around $77 million.
• Discussions for selling Parcus Medical are just starting.

Anika Therapeutics is significantly transforming by focusing on high-potential HA-based products for OA pain management. These divestiture strategies and emphasis on product innovation position Anika for future growth and profitability while maintaining careful financial management.

InvestingPro Insights

Anika's recent strategic decisions and financial updates come with a challenging stock performance, showing a 32.03% drop in the past week and a 34.61% decline over the last month. However, positive indicators hint at a potential turnaround as net income is expected to grow this year.

Currently, Anika's stock trades near its 52-week low, with a price-to-book ratio of 1.36, possibly indicating a value opportunity for long-term investors.

Full Transcript – Anika Therapeutics Inc (ANIK) Q3 2024

Operator

Good morning, ladies and gentlemen, and welcome to Anika's Third Quarter Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, October 31, 2024. I will now turn the call over to Matt Hall, Director, Corporate Development and Investor Relations. Please proceed.

Matt Hall

Thank you. Good morning, and thank you for joining us for Anika's third quarter 2024 conference call and webcast. I joined Anika 2.5 years ago in Business Development and have recently taken over Investor Relations responsibilities from Mark, who exited the company earlier this quarter. Our Q3 earnings press release was issued earlier this morning, available on Anika's Investor Relations website. Certain statements made during the call constitute forward-looking statements subject to certain risks. Please refer to our most recent SEC filings for details about risk factors that might affect our performance.

Cheryl Blanchard

Today marks an important day in the Anika story. Earlier today, we sold Arthrosurface and intend to sell Parcus Medical. We concluded that these products would be better suited at another company due to unmet commercial synergies and regulatory complexities. We expect to reduce our global headcount from 325 to 225 employees. Anika's strategy focuses on differentiated HA-based products that will improve shareholder returns.

Steve Griffin

In Q3, Anika reported $38.8 million in total revenue, down from last year. This decline was mainly driven by lower revenue from the JNJ Medtech partnership and falls in Arthrosurface sales. The net loss for the quarter was $29.9 million, primarily affected by the Arthrosurface impairment. We expect $16 million to $18 million in adjusted EBITDA for 2024, reflecting initiatives for long-term profitability.

Closing

The results of our strategic review represent an important pivot for Anika, focusing on Regenerative Solutions and OA pain management products. Thank you for joining us today, and now we will open the line for questions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.